MedTrace Logo

A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors

NCT00907205 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice per week for 4 weeks and ultimately define a recommended phase II dose.

Conditions

  • Advanced or Metastatic Solid Tumors
  • Cancer
  • Solid Cancers

Interventions

DRUG

SF1126

Dose Escalating with 3+ patients in each cohort

Sponsors & Collaborators

  • SignalRX Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Semafore Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Donald L Durden, MD, PhD · SignalRX Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-01-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00907205 on ClinicalTrials.gov